Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
GOAL: By systematic review, we assessed the impact of fecal microbiota transplantation (FMT) for the treatment of Clostridium difficile (CD)-associated diarrhea. BACKGROUND: Fecal microbiota microbiota transplantation from a healthy donor into an individual with CD infection (CDI) can resolve symptoms. STUDY: We conducted systematic searches in PubMed, SCOPUS, Web of Science, and Cochrane Library. The last search was run on February 8, 2013. The following Medical Subject Headings terms and keywords were used alone or in combination: Clostridium difficile; Clostridium infection; pseudomembranous colitis; feces; stools; fecal suspension; fecal transplantation; fecal transfer; fecal infusion; microbiota; bacteriotherapy; enema; nasogastric tube; colonoscopy; gastroscopy; fecal donation; donor. A critical appraisal of the clinical research evidence on the effectiveness and safety of FMT for the treatment of patients with CD-associated diarrhea was made. RESULTS: Twenty full-text case series, 15 case reports, and 1 randomized controlled study were included for the final analysis. Almost all patients treated with donors' fecal infusion experienced recurrent episodes of CD-associated diarrhea despite standard antibiotic treatment. Of a total of 536 patients treated, 467 (87%) experienced resolution of diarrhea. Diarrhea resolution rates varied according to the site of infusion: 81% in the stomach; 86% in the duodenum/jejunum; 93% in the cecum/ascending colon; and 84% in the distal colon. No severe adverse events were reported with the procedure. CONCLUSIONS: FMT seems efficacious and safe for the treatment of recurrent CDI. Hospitals should encourage the development of fecal transplantation programs to improve therapy of local patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most clinical trials and systemic reviews presented that some minor adverse events, such as abdominal discomfort, diarrhea, constipation, and low-grade fever, were transiently noted after FMT, and uncommon severe side effects were often associated with the possible complications of endoscopy and sedation.17,19,66,70,71”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [66]
In the citing paper
“Numerous case reports, retrospective case series and a single randomized controlled trial have demonstrated benefit of FMT in patients with severe or recurrent CDI with cure rates as high as 100% and a mean cure rate of 87–90% for the over 500 cases reported in the world literature to date.3–5”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [3]
In the citing paper
“of the over 500 cases reported to date3, FMT has demonstrated rapid response and a cure rate of nearly 90%, with a negligible significant adverse event rate, regardless of route.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [3]
In the citing paper
“In a systematic review, Cammarota et al. observed that lower gastrointestinal route (colonoscopy, enema) led to the achievement of higher eradication rates than upper delivery (gastroscopy, nasogastric or nasointestinal tube) (81–86% vs 84–93%, respectively)3.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [3]
In the citing paper
“Numerous case reports, retrospective case series and a single randomized controlled trial have demonstrated benefit of FMT in patients with severe or recurrent CDI with cure rates as high as 100% and a mean cure rate of 87–90% for the over 500 cases reported in the world literature to date.3–5”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [3]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Kassam et al33 Canada 27 69 (26-87) Recurrent (NR)/First episode (refractory) Distal colon/ enema 150/300 25/NR Mean 14mo O: M-V (also associated)”
BackgroundCohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020
Research works printed but not linked: 3
- Lund-Tonnesen, 1998, . Clostridium difficile-associated diarrhoea treated with homologous faeces., Tidsskr Nor Laegeforen, 118, 1027
- Harkonen, 1996, Recurrent pseudomembranous colitis treated with the donor feces., Duodecim, 112, 1803
- Fenton, 1974, Pseudomembranous colitis associated with antibiotic therapyan emerging entity., Can Med Assoc J, 111, 1110
Cited by
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Self-citationFactors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615
“Physical functioning 45 (20-70) 35 (20-65)”
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Metadata
- Authors
- Cammarota, G., Ianiro, G., & Gasbarrini, A.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2014-09
- Volume
- 48
- Issue
- 8
- Pages
- 693-702
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W1963864447
- Cited by
- 428
- References
- 62
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 29 · 2023: 27 · 2022: 38 · 2021: 34 · 2020: 30 · 2019: 38 · 2018: 48 · 2017: 45 · 2016: 45 · 2015: 46 · 2014: 21
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, Clostridium difficile infection, pseudomembranous colitis, recurrent Clostridium difficile infection, enema, nasogastric tube, colonoscopy, treatment efficacy, safety
- MeSH terms
- Anti-Bacterial Agents, Clostridium Infections, Diarrhea, Feces, Humans, Recurrence, Clostridioides difficile, Treatment Outcome, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. https://app.cochat.ai/papers/10.1097/mcg.0000000000000046
- The paper
- Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014). Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0000000000000046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.